ARA-290, also known as cibinetide, is a synthetic peptide derivative of erythropoietin (EPO) designed to selectively target the innate repair receptor (IRR) without activating the erythropoietic pathway. Structurally, it is an 11–amino acid peptide modeled from the B-helix region of EPO, engineered to retain tissue-protective properties while avoiding stimulation of red blood cell production.
In research contexts, ARA-290 is studied for its interaction with the IRR, a heteromeric complex composed of the erythropoietin receptor (EPOR) and the β-common receptor (CD131). This receptor complex has been implicated in cellular signaling pathways related to anti-inflammatory responses, tissue protection, and repair mechanisms.
Due to its targeted receptor activity and short peptide structure, ARA-290 has attracted attention in preclinical and clinical studies exploring metabolic regulation, immune modulation, and neuroprotection.
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Not for human consumption
Targeted Innate Repair Receptor Activity
ARA-290 is studied for its selective interaction with the innate repair receptor, a receptor complex composed of the erythropoietin receptor (EPOR) and the β-common receptor (CD131). Activation of this pathway has been associated in research models with cellular protection, inflammatory regulation, and restoration of tissue homeostasis following stress or injury.
Unlike full-length erythropoietin, ARA-290 was designed to retain tissue-protective signaling properties while minimizing stimulation of hematopoietic activity.
Reviews
There are no reviews yet.